Research programme: antibody-drug conjugates - Adimab/Mersana Therapeutics

Drug Profile

Research programme: antibody-drug conjugates - Adimab/Mersana Therapeutics

Alternative Names: Fleximer®-ADC - Adimab/Mersana Therapeutics; Trastuzumab-m-Dolaflexin®; Trastuzumab-s-Dolaflexin®; XMT-1535

Latest Information Update: 18 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adimab; Mersana Therapeutics
  • Class Antineoplastics; Depsipeptides; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 14 May 2018 Mersana Therapeutics has patent protection in USA and foreign countries across its platforms and programmes
  • 30 Oct 2017 Mersana Therapeutics plans a phase I trial for XMT 1536 in Cancer in early 2018 (CTP#279524)
  • 09 Mar 2017 Mersana Therapeutics has patent protection for Fleximer-ADC platform technology in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top